{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:18:51Z","timestamp":1791998331940,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12098-023-04819-y","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T09:02:14Z","timestamp":1695373334000},"page":"391-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chronic Liver Disease \u2013 What\u2019s New?"],"prefix":"10.1007","volume":"91","author":[{"given":"Ezyana","family":"Effandie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9026-1583","authenticated-orcid":false,"given":"Girish L.","family":"Gupte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"4819_CR1","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1056\/NEJMra1300575","volume":"372","author":"DC Rockey","year":"2015","unstructured":"Rockey DC, Bell PD, Hill JA. Fibrosis - a common pathway to organ injury and failure. N Engl J Med. 2015;372:1138\u201349.","journal-title":"N Engl J Med"},{"key":"4819_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209\u201318.","journal-title":"J Clin Invest"},{"key":"4819_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1440-1746.2011.07002.x","volume":"27","author":"K Iwaisako","year":"2012","unstructured":"Iwaisako K, Brenner DA, Kisseleva T. What\u2019s new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol. 2012;27:65\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"4819_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.7326\/0003-4819-127-11-199712010-00006","volume":"127","author":"J-F Dufour","year":"1997","unstructured":"Dufour J-F, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med. 1997;127:981\u20135.","journal-title":"Ann Intern Med"},{"key":"4819_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007708","volume":"96","author":"AD Borss\u00e9n","year":"2017","unstructured":"Borss\u00e9n AD, Palmqvist R, Kechagias S, et al. Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis. Medicine. 2017;96:e7708.","journal-title":"Medicine"},{"key":"4819_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/liv.12576","volume":"35","author":"E Akhtar","year":"2015","unstructured":"Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained viral response after antiviral treatment: a meta-analysis. Liver Int. 2015;35:30\u20136.","journal-title":"Liver Int"},{"key":"4819_CR7","volume":"9","author":"Z Tan","year":"2021","unstructured":"Tan Z, Sun H. Liver fibrosis: therapeutic target and advances in drug therapy. Frontiers. 2021;9:730176.","journal-title":"Frontiers"},{"key":"4819_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0065-2423(08)00404-6","volume":"46","author":"T Poynard","year":"2008","unstructured":"Poynard T, Morra R, Ingiliz P, et al. Biomarkers of liver fibrosis. Adv Clin Chem. 2008;46:131\u201360.","journal-title":"Adv Clin Chem"},{"key":"4819_CR9","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/jgh.13668","volume":"32","author":"S Bertrais","year":"2017","unstructured":"Bertrais S, Boursier J, Ducancelle A, et al. Prognostic durability of liver fibrosis tests and improvement in predictive performance for mortality by combining tests. J Gastroenterol Hepatol. 2017;32:1240\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"4819_CR10","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"C-T Wai","year":"2003","unstructured":"Wai C-T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518\u201326.","journal-title":"Hepatology"},{"key":"4819_CR11","unstructured":"Curry M, Afdhal N. Noninvasive assessment of hepatic fibrosis: overview of serologic and radiographic tests. UpToDate. 2020. Available at: https:\/\/www.uptodate.com\/contents\/noninvasive-assessment-of-hepatic-fibrosis-overview-of-serologic-and-radiographic-tests? Accessed on 20 Oct 2022."},{"key":"4819_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hep.24105","volume":"53","author":"Z-H Lin","year":"2011","unstructured":"Lin Z-H, Xin Y-N, Dong Q-J, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C- related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726\u201336.","journal-title":"Hepatology"},{"key":"4819_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"4819_CR14","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","volume":"145","author":"P Angulo","year":"2013","unstructured":"Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782-9.e4.","journal-title":"Gastroenterology"},{"key":"4819_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006336","volume":"96","author":"QM Li","year":"2017","unstructured":"Li QM, Ren X, Lu C, Li W, Huang Y, Chen L. Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT \u22642 ULN. Medicine. 2017;96:e6336.","journal-title":"Medicine"},{"key":"4819_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/hep.21984","volume":"47","author":"I Guha","year":"2008","unstructured":"Guha I, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2008;47:455\u201360.","journal-title":"Hepatology"},{"key":"4819_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092772","volume":"9","author":"Q Xie","year":"2014","unstructured":"Xie Q, Zhou X, Huang P, Wei J, Wang W, Zheng S. The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis. PLoS ONE. 2014;9:e92772.","journal-title":"PLoS ONE"},{"key":"4819_CR18","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/liv.12584","volume":"35","author":"S Petta","year":"2015","unstructured":"Petta S, Vanni E, Bugianesi E, et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2015;35:1566\u201373.","journal-title":"Liver Int"},{"key":"4819_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Cast\u00e9ra","year":"2005","unstructured":"Cast\u00e9ra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343\u201350.","journal-title":"Gastroenterology"},{"key":"4819_CR20","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1136\/gutjnl-2017-314249","volume":"66","author":"SP O'Hara","year":"2017","unstructured":"O\u2019Hara SP, Karlsen TH, LaRusso NF. Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link? Gut. 2017;66:1873\u20137.","journal-title":"Gut"},{"key":"4819_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.20632","volume":"41","author":"R Wiest","year":"2005","unstructured":"Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005;41:422\u201333.","journal-title":"Hepatology"},{"key":"4819_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4161\/gmic.28684","volume":"5","author":"JS Bajaj","year":"2014","unstructured":"Bajaj JS. The role of microbiota in hepatic encephalopathy. Gut Microbes. 2014;5:397\u2013403.","journal-title":"Gut Microbes"},{"key":"4819_CR23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.14218\/JCTH.2019.00056","volume":"8","author":"CA Philips","year":"2020","unstructured":"Philips CA, Augustine P, Yerol PK, et al. Modulating the intestinal microbiota: therapeutic opportunities in liver disease. J Clin Transl Hepatol. 2020;8:87\u201399.","journal-title":"J Clin Transl Hepatol"},{"key":"4819_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/MPG.0000000000002973","volume":"72","author":"V Jain","year":"2021","unstructured":"Jain V, Alexander EC, Burford C, Verma A, Dhawan A. Gut microbiome: a potential modifiable risk factor in biliary atresia. J Pediatr Gastroenterol Nutr. 2021;72:184\u201393.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4819_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/jgh.14777","volume":"35","author":"J Wang","year":"2020","unstructured":"Wang J, Qian T, Jiang J, et al. Gut microbial profile in biliary atresia: a case-control study. J Gastroenterol Hepatol. 2020;35:334\u201342.","journal-title":"J Gastroenterol Hepatol"},{"key":"4819_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/17474124.2018.1481747","volume":"12","author":"FR Ponziani","year":"2018","unstructured":"Ponziani FR, Zocco MA, Cerrito L, Gasbarrini A, Pompili M. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol. 2018;12:641\u201356.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"4819_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/microbiolres13030038","volume":"13","author":"F Santopaolo","year":"2022","unstructured":"Santopaolo F, Coppola G, Giuli L, Gasbarrini A, Ponziani FR. Influence of gut\u2013liver axis on portal hypertension in advanced chronic liver disease: the gut microbiome as a new protagonist in therapeutic management. Microbiol Res. 2022;13:539\u201355.","journal-title":"Microbiol Res"},{"key":"4819_CR28","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","volume":"9","author":"SB Ahn","year":"2019","unstructured":"Ahn SB, Jun DW, Kang BK, Lim JH, Lim S, Chung MJ. Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep. 2019;9:5688.","journal-title":"Sci Rep"},{"key":"4819_CR29","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1097\/MCG.0b013e318169c44e","volume":"42","author":"AA Sheth","year":"2008","unstructured":"Sheth AA, Garcia-Tsao G. Probiotics and liver disease. J Clin Gastroenterol. 2008;42:S80\u20134.","journal-title":"J Clin Gastroenterol"},{"key":"4819_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/MEG.0000000000002567","volume":"35","author":"J Shi","year":"2023","unstructured":"Shi J, Li F. Clinical study of probiotics combined with lactulose for minimal hepatic encephalopathy treatment. Eur J Gastroenterol Hepatol. 2023;35:777\u201381.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4819_CR31","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/nutrit\/nuy031","volume":"76","author":"BR Loman","year":"2018","unstructured":"Loman BR, Hern\u00e1ndez-Saavedra D, An R, Rector RS. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutr Rev. 2018;76:822\u201339.","journal-title":"Nutr Rev"},{"key":"4819_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.774335","volume":"12","author":"J Liu","year":"2022","unstructured":"Liu J, Yang D, Wang X, et al. Gut microbiota targeted approach in the management of chronic liver diseases. Front Cell Infect Microbiol. 2022;12:774335.","journal-title":"Front Cell Infect Microbiol"},{"key":"4819_CR33","unstructured":"British Society of Gastroenterology, McPherson S, Thompson. Management of hepatic encephalopathy: beyond the acute episode. 2019 [Updated on 8 Feb. 2023]. Available at: https:\/\/www.bsg.org.uk\/web-education-articles-list\/management-of-hepatic-encephalopathy-beyond-the-acute-episode-dr-mcpherson-and-dr-thompson-provides-insight-into-the-management-of-hepatic-encephalopathy\/. Accessed on 20 Oct 2022."},{"key":"4819_CR34","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2165\/00003495-199549030-00009","volume":"49","author":"JC Gillis","year":"1995","unstructured":"Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995;49:467\u201384.","journal-title":"Drugs"},{"key":"4819_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/HMER.S11988","volume":"3","author":"MD Iadevaia","year":"2011","unstructured":"Iadevaia MD, Prete AD, Cesaro C, Gaeta L, Zulli C, Loguercio C. Rifaximin in the treatment of hepatic encephalopathy. Hepat Med. 2011;3:109\u201317.","journal-title":"Hepat Med"},{"key":"4819_CR36","doi-asserted-by":"publisher","first-page":"8355","DOI":"10.3748\/wjg.v23.i47.8355","volume":"23","author":"K Kaji","year":"2017","unstructured":"Kaji K, Takaya H, Saikawa S, et al. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol. 2017;23:8355\u201366.","journal-title":"World J Gastroenterol"},{"key":"4819_CR37","doi-asserted-by":"crossref","unstructured":"Xu HM, Huang HL, Zhou YL, et al. Fecal microbiota transplantation: a new therapeutic attempt from the gut to the brain. Gastroenterol Res Pract. 2021;2021:6699268.","DOI":"10.1155\/2021\/6699268"},{"key":"4819_CR38","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/hep.29646","volume":"67","author":"T Garc\u00eda-Lezana","year":"2018","unstructured":"Garc\u00eda-Lezana T, Raurell I, Bravo M, et al. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. Hepatology. 2018;67:1485\u201398.","journal-title":"Hepatology"},{"key":"4819_CR39","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","volume":"7","author":"D Zhou","year":"2017","unstructured":"Zhou D, Pan Q, Shen F, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 2017;7:1529.","journal-title":"Sci Rep"},{"key":"4819_CR40","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","volume":"114","author":"JR Allegretti","year":"2019","unstructured":"Allegretti JR, Kassam Z, Carrellas M, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol. 2019;114:1071\u20139.","journal-title":"Am J Gastroenterol"},{"key":"4819_CR41","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1172\/JCI76738","volume":"125","author":"C Jiang","year":"2015","unstructured":"Jiang C, Xie C, Li F, et al. Intestinal Farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2015;125:386\u2013402.","journal-title":"J Clin Invest"},{"key":"4819_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151829","volume":"11","author":"M Mouzaki","year":"2016","unstructured":"Mouzaki M, Wang AY, Bandsma R, et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS ONE. 2016;11:e0151829.","journal-title":"PLoS ONE"},{"key":"4819_CR43","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hep.28709","volume":"65","author":"JP Arab","year":"2017","unstructured":"Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology. 2017;65:350\u201362.","journal-title":"Hepatology"},{"key":"4819_CR44","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","volume":"71","author":"M Trauner","year":"2022","unstructured":"Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut. 2022;71:194\u2013209.","journal-title":"Gut"},{"key":"4819_CR45","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, et al. POISE Study Group. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631\u201343.","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-023-04819-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12098-023-04819-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-023-04819-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:59:53Z","timestamp":1710327593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12098-023-04819-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["4819"],"URL":"https:\/\/doi.org\/10.1007\/s12098-023-04819-y","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"12 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}